Stk39-flox Mouse
一般名
Stk39-flox
製品ID
S-CKO-11611
背景情報
C57BL/6NCya
系統ID
CKOCMP-53416-Stk39-B6N-VA
状況
このマウス系統を論文で使用する場合は、「Stk39-flox Mouse(カタログ番号S-CKO-11611)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Stk39-flox
系統ID
CKOCMP-53416-Stk39-B6N-VA
遺伝子名
製品ID
S-CKO-11611
遺伝子別名
DCHT, Rnl5, SPAK, RF005, Gm50618
遺伝子別名
C57BL/6NCya
NCBI ID
修正
Conditional knockout
染色体
Chr 2
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000102715
NCBIトランスクリプトID
NM_016866
ターゲット領域
Exon 2
有効領域の大きさ
~2.0 kb
遺伝子研究の概要
Stk39, a serine/threonine kinase, is involved in multiple crucial biological functions. It participates in DNA damage response pathways, with ATM kinase phosphorylating Stk39 after DNA damage, enabling it to interact with the Mre11-Rad50-Nbs1 complex, recruit to chromatin, and further phosphorylate H2A.X, promoting homologous recombination repair [1]. It also has a role in several signaling pathways such as the PLK1/ERK, PI3K/AKT, and is associated with various diseases including different types of cancers and hypertension.
In cancer research, knockdown of Stk39 in various cancer cell lines shows inhibitory effects. In hepatocellular carcinoma, its depletion attenuated cell growth, metastasis, arrested the cell cycle in G2/M phase, and promoted apoptosis, with Stk39 positively regulating the ERK signaling pathway [2]. In cholangiocarcinoma, Stk39 knockdown suppressed cell proliferation, migration, and invasion, while overexpression facilitated tumor aggressiveness, and it enhanced the progression by activating the PI3K/AKT signaling pathway [3]. In breast cancer, inhibition of Stk39 via knockdown led to SNAI1 destabilization, impairing the EMT phenotype and decreasing tumor cell migration, invasion, and metastasis [4]. In osteosarcoma, Stk39 down-regulation inhibited cell proliferation and invasion, affecting proteins related to these processes [6]. In pancreatic cancer, downregulation of circ-STK39, which is derived from Stk39, suppressed cancer progression [7]. In renal cell carcinoma, suppressing Stk39 expression significantly suppressed cell proliferation and induced apoptosis, with gene set enrichment analysis identifying it as an important regulator of p53 and p38 signaling pathways [9]. Also, in hepatocellular carcinoma, knockdown of Stk39 suppressed cell proliferation, migration, and invasion by repressing the phosphorylation of mitogen-activated protein kinase p38 [8].
In conclusion, Stk39 plays essential roles in DNA damage repair and is significantly involved in the progression of multiple cancers, as revealed by various loss-of-function experiments. These findings suggest that Stk39 could be a potential therapeutic target for treating cancers. Additionally, its association with hypertension indicates its importance in non-cancerous disease areas as well [5].
References:
1. Xu, Yi, Li, Changying, Yin, Huan, Yi, Junlin, Deng, Min. . STK39-mediated amplification of γ-H2A.X promotes homologous recombination and contributes to PARP inhibitor resistance. In Nucleic acids research, 52, 13881-13895. doi:10.1093/nar/gkae1099. https://pubmed.ncbi.nlm.nih.gov/39588777/
2. Zhang, Chengfei, Wang, Xiaoming, Fang, Dan, Hui, Kam Man, Xia, Hongping. 2021. STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway. In Theranostics, 11, 2108-2122. doi:10.7150/thno.48112. https://pubmed.ncbi.nlm.nih.gov/33500714/
3. Hao, Xiaopei, Zhang, Yao, Lu, Yiwei, Wu, Jindao, Wang, Xuehao. 2021. STK39 enhances the progression of Cholangiocarcinoma via PI3K/AKT pathway. In iScience, 24, 103223. doi:10.1016/j.isci.2021.103223. https://pubmed.ncbi.nlm.nih.gov/34746696/
4. Qiu, Zhaoping, Dong, Bo, Guo, Weijie, Evers, B Mark, Wu, Yadi. 2021. STK39 promotes breast cancer invasion and metastasis by increasing SNAI1 activity upon phosphorylation. In Theranostics, 11, 7658-7670. doi:10.7150/thno.62406. https://pubmed.ncbi.nlm.nih.gov/34335956/
5. Xi, Bo, Chen, Man, Chandak, Giriraj R, He, Juan, Mou, Si-Hua. 2013. STK39 polymorphism is associated with essential hypertension: a systematic review and meta-analysis. In PloS one, 8, e59584. doi:10.1371/journal.pone.0059584. https://pubmed.ncbi.nlm.nih.gov/23527223/
6. Huang, Tao, Zhou, Yuan, Cao, Yun, Zhou, Zhi-Hui, Hang, Dong-Hua. 2017. STK39, overexpressed in osteosarcoma, regulates osteosarcoma cell invasion and proliferation. In Oncology letters, 14, 4599-4604. doi:10.3892/ol.2017.6728. https://pubmed.ncbi.nlm.nih.gov/28943960/
7. Li, Chao, Cai, Juanjuan, Liu, Weifeng, Gao, Zhenzhen, Li, Guogang. 2023. Downregulation of circ-STK39 suppresses pancreatic cancer progression by sponging mir-140-3p and regulating TRAM2-mediated epithelial-mesenchymal transition. In Apoptosis : an international journal on programmed cell death, 28, 1024-1034. doi:10.1007/s10495-023-01813-9. https://pubmed.ncbi.nlm.nih.gov/37041422/
8. Chen, Jian, Zhou, Luke, Yang, Jie, Liu, Lin, Li, Youwei. . Knockdown of STK39 suppressed cell proliferation, migration, and invasion in hepatocellular carcinoma by repressing the phosphorylation of mitogen-activated protein kinase p38. In Bioengineered, 12, 6529-6537. doi:10.1080/21655979.2021.1973876. https://pubmed.ncbi.nlm.nih.gov/34519635/
9. Zhao, Qi, Zhu, Yanjun, Liu, Li, Hu, Xiaoyi, Guo, Jianming. 2018. STK39 blockage by RNA interference inhibits the proliferation and induces the apoptosis of renal cell carcinoma. In OncoTargets and therapy, 11, 1511-1519. doi:10.2147/OTT.S153806. https://pubmed.ncbi.nlm.nih.gov/29588603/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
